Evidence map›Paper›PMID 19841036›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2010

CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs.

Ebbe Billmann Thorgersen, Bernt Christian Hellerud, Erik Waage Nielsen, Andreas Barratt-Due, Hilde Fure, Julie Katrine Lindstad, Anne Pharo, Erik Fosse, Tor Inge Tønnessen, Harald Thidemann Johansen and 2 more

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Effect of antiplatelet agents onFrontiers in microbiology · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Frontiers in veterinary science · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ebbe Billmann ThorgersenInstitute of Immunology, Rikshospitalet University Hospital, N-0027 Oslo, Norway. ebbtho@rr-research.no
Bernt Christian Hellerud
Erik Waage Nielsen
Andreas Barratt-Due
Hilde Fure
Julie Katrine Lindstad
Anne Pharo
Erik Fosse
Tor Inge Tønnessen
Harald Thidemann Johansen
Albert Castellheim
Tom Eirik Mollnes
Oslo University Hospital · NOUniversity of Oslo · NONordland Hospital · NOUiT The Arctic University of Norway · NO

Funding

Biomaterial-induced complement activationR01EB003968 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI LAMBRIS, JOHN D · 2005 to 2008
$1.0M
NIBIB NIH HHS R01 EB003968NIBIB NIH HHS R01 EB003968-01A1
6 · The paper itself

Abstract

Sepsis is a severe infection-induced systemic inflammatory syndrome. Inhibition of downstream inflammatory mediators of sepsis, e.g., TNF-alpha, has failed in clinical trials. The aim of this study was to investigate the effects of inhibiting CD14, a key upstream innate immunity molecule, on the early inflammatory and hemostatic responses in a pig model of gram-negative sepsis. The study comprised two arms, whole live Escherichia coli bacteria and E. coli lipopolysaccharide (LPS) (n=25 and n=9 animals, respectively). The animals were allocated into treatment (anti-CD14) and control (IgG isotype or saline) groups. Inflammatory, hemostatic, physiological, and microbiological parameters were measured. The proinflammatory cytokines TNF-alpha, IL-1beta, IL-6, and IL-8, but not the anti-inflammatory cytokine IL-10, were efficiently inhibited by anti-CD14. Furthermore, anti-CD14 preserved the leukocyte count and significantly reduced granulocyte enzyme matrix metalloproteinase-9 release and expression of the granulocyte membrane activation molecule wCD11R3 (pig CD11b). The hemostatic markers thrombin-antithrombin III complexes and plasminogen activator inhibitor-1 were significantly attenuated. Anti-CD14 did not affect LPS or E. coli DNA levels. This study documents that CD14 inhibition efficiently attenuates the proinflammatory cytokine response and granulocyte activation and reverses the procoagulant state but does not interfere with LPS levels or bacterial counts in E. coli-induced sepsis.-Thorgersen, E. B., Hellerud, B. C., Nielsen, E. W., Barratt-Due, A., Fure, H., Lindstad, J. K., Pharo, A., Fosse, E., Tønnessen, T. I., Johansen, H. T., Castellheim, A., Mollnes, T. E. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs.

Indexed as

AnimalsAntibodies, MonoclonalEscherichia coliFemaleFlow CytometryInterleukin-1betaInterleukin-6Interleukin-8Lipopolysaccharide ReceptorsLipopolysaccharidesMaleSepsisSwineTumor Necrosis Factor-alphaAntibodies, MonoclonalInterleukin-1betaInterleukin-6Interleukin-8Lipopolysaccharide ReceptorsLipopolysaccharidesTumor Necrosis Factor-alpha

Identifiers

PMID19841036
PMCPMC2830134
OpenAlexW2160903934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.